ITGAX and asthma: Importantly, the therapeutic administration of act-A-iTreg cells in an Ova-induced allergic airway inflammation mouse model conferred significant protection against asthma manifestations, associated with markedly decreased frequencies of activated CD11c+MHCIIhigh cDCs in the lung-draining MLNs [105].